SHOWNOTES
A brisk, data-driven run through Exhibits A–C (U.S. finances, Natural Gas, Oil), followed by a condensed “History of OpenAI,” semis capacity pinch points, a Tesla check-in, and timely healthcare policy updates.
[00:00] Intro
[00:47] Exhibit C: Oil—Geopolitics & The Abraham Accords Path
Discussion of a proposed Gaza plan reportedly backed by regional governments and the potential for broader normalization—implications for oil risk premia and global supply/demand. The team underscores how political stabilization could pressure crude pricing while reshaping Middle East dynamics.
[02:25] Exhibit B: Natural Gas—Differentials & Permian Activity
Waha basis blowouts (−$6 to −$7) tied to maintenance heading to the Gulf Coast; relief expected as maintenance ends. Team notes curtailments in the Permian and how depressed Waha prices could temper gas supply growth despite a longer-term ~108 bcf/d 2026 view.
[03:51] Exhibit A: U.S. Government Finances—Regular Order vs. CRs
All 12 House appropriations bills passed; several in conference with the Senate. If completed, “regular order” could be a real fiscal process improvement; timing risk remains around near-term pay cycles and political tactics.
[06:54] The History of OpenAI
From 2015 nonprofit roots to capped-profit restructuring in 2019, Microsoft’s early backing, and the GPT-1→2→3 progression culminating in ChatGPT’s breakout adoption. The hosts highlight governance tension, talent churn, and the compute arms race driving massive capex, alongside OpenAI’s push into consumer and enterprise features.
[19:02] Next Week’s History: Oracle—From Cash Machine to Capex Engine (p. 2)
Teaser for Oracle’s pivot into massive AI infrastructure spend, its OpenAI linkage, and whether financing can keep pace with ambition.
[20:16] Semis Stack & The Compute Bottleneck (NVDA/AMD/INTC/TSMC/ASML) (p. 3)
Page 3 spotlight: NVDA leadership vs. AMD incentives, Intel’s moves, and why TSMC’s process capacity is the current “choke point.” The crew argues TSMC’s pricing power is underexercised relative to its moat and strategic position.
[23:07] Tesla: Model Y Trim, FSD v14, and Product Roadmap Expectations (pp. 10–11 if applicable)
Market hoped for a ~$30k EV; instead a lower-cost Model Y variant and ongoing robo-taxi focus. FSD v14 early feedback looks improved; rumors swirl (Roadster, new propulsion/downforce concepts), but capital markets still weigh valuation vs. cash generation.
[26:16] Healthcare News: TrumpRx Mechanics & Medicare Math (Exhibit A; Healthcare pages)
Refined estimate places Medicare Part D government spend near ~$140B (older figure), with potential savings in the ~$70B range depending on design. Key operational unknowns (coverage vs. out-of-pocket) and how thresholds interact with the $2,000 OOP max.
[27:21] Tariffs on Patented Pharma & CDMO Workarounds (Healthcare pages)
100% tariff headline risk appears mitigable—onshoring or contracting U.S. CDMOs can offset. Given high gross margins post-R&D, the sector sighs relief versus harsher scenarios.
[28:01] The Case for the Almighty Dollar (Exhibit A)
If spending levels stabilize and healthcare growth moderates, the U.S. deficit could trend from ~$1.9T toward ~$1.4–1.5T. Hosts contrast U.S. trajectories with other majors; note gold strength vs. a firming dollar as markets reassess fiscal momentum.
[30:32] Outro
Thanks for listening! If the episode helped your investing framework, share it with a friend and grab the latest Cash Flow Memo for all 80+ company updates and Exhibits A–C.
This podcast and the information herein are intended for informational purposes only. The views expressed herein are the author’s alone and do not constitute an offer to sell, or a recommendation to purchase, or a solicitation of an offer to buy, any security, nor a recommendation for any investment product or service. While certain information contained herein has been obtained from sources believed to be reliable, neither the author nor any of his employers or their affiliates have independently verified this information, and its accuracy and completeness cannot be guaranteed. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, timeliness or completeness of this information. The author and all employers and their affiliated persons assume no liability for this information and no obligation to update the information or analysis contained herein in the future.
